Business
US Patents Granted for ARIUS Antibodies
US Patents Granted for ARIUS Antibodies.
About this update from Affinity Metals Corp
[{"type":"text","content":"\n\n\n\nARIUS' "target on the target" protected\n\n\nTSX: ARI\n\n\nTORONTO, March 8 /CNW/ - ARIUS Research Inc. (TSX: ARI) announced today\nthat it has been granted two new United States patents for antibodies within\ntheir CD63 program. Patent 7,175,846. covers anti-cancer antibodies in ARIUS'\npartnered program for melanoma, breast and prostate cancers and protects the\nvaluable site on the disease target that the drug candidate binds to. The\nCompany's FunctionFIRST(TM) platform uses a unique process to discover\nantibody drugs by identifying those that destroy cancer cells while leaving\nnormal cells alone. In the process the antibodies can attach themselves to the\ncancer cell but they must hit the appropriate spot on the cell i.e. the\n"target on the target", in order to destroy it. ARIUS' patent strategy has\nsuccessfully captured the discovery process, the antibody drug molecules and\nnow the spot on the target that is key to causing the cancer cell's\ndestruction.\n\n\nPatent 7,186,808 covers a second antibody within this program that kills\nbreast and prostate cancer cells. The patent also covers the use of the\nantibody as a treatment for breast cancer.\n\n\nARIUS has over 120 patents pending that will continue to enhance the\nvalue of the company.\n\n\n"This patent provides additional commercial and scientific validation to\nour drug discovery platform," said Dr. David Young, President and CEO of\nARIUS. "Our unique approach allows us to extract new value from a wide range\nof cancer targets while identifying drug candidates that can be developed to\nhelp patients."\n\n\nARIUS Research Inc. is a biotechnology company dedicated to the discovery\nand development of novel anticancer monoclonal antibodies (MAbs) focused on\ndestroying cancer cells. Established in 1999, ARIUS has built a proprietary\ntechnology platform, FunctionFIRST(TM), that rapidly identifies powerful MAbs\ntargeting a variety of cancer indications. This antibody generation engine has\nenabled ARIUS to assemble a growing pipeline, which is used for commercial\ncollaborations and in-house development. ARIUS has ongoing partnerships with\nkey biotechnology and drug development companies. The company is listed on the\nTSX under the symbol "ARI".\n\n\nForward-Looking Statement\n\n\nCertain statements in th...